Literature DB >> 10953123

Serum immunosuppressive acidic protein and natural killer cell activity in patients with metastatic renal cell carcinoma before and after nephrectomy.

K Fujikawa1, Y Matsui, K Miura, T Kobayashi, H Oka, S Fukuzawa, H Takeuchi.   

Abstract

PURPOSE: To our knowledge the impact of nephrectomy on stage M1 renal cell carcinoma remains to be determined. We previously reported that nephrectomy is beneficial in patients with elevated serum C-reactive protein before treatment, and those in whom nadir C-reactive protein decreases postoperatively to within the normal range may expect longer survival when surgery is combined with postoperative immunotherapy. In this study we determine the effect of nephrectomy on the immune response in patients with metastatic renal cell carcinoma.
MATERIALS AND METHODS: We retrospectively reviewed the records of 40 patients with metastatic renal cell carcinoma diagnosed at our institution between 1986 and 1999. These patients underwent nephrectomy before cytokine therapy with interferon. Before and after nephrectomy we measured serum C-reactive protein, serum immunosuppressive acidic protein and peripheral blood natural killer cell activity.
RESULTS: In 15 patients with pretreatment serum C-reactive protein within the normal range (less than 1 ng./ml.) there was no significant difference before and after nephrectomy in the serum immunosuppressive acidic protein level or natural killer cell activity (p = 0.4587 and 0.3892, respectively). On the other hand, in 25 patients with serum C-reactive protein elevated before treatment to 1 ng./ml. or greater serum immunosuppressive acidic protein decreased significantly and natural killer cell activity increased significantly after cytoreductive surgery (p = 0.0002 and 0.0286, respectively).
CONCLUSIONS: Our study implies that nephrectomy may be beneficial in patients with elevated serum C-reactive protein before treatment. Further evaluation by a prospective study is needed to make a definitive conclusion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10953123     DOI: 10.1097/00005392-200009010-00013

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  Prognostic value of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: a meta-analysis.

Authors:  Xuwei Hong; Fei Li; Kaiqiang Tang; Shiyu Pang; Guangzheng Lin; Shi Li; Jiming Bao; Wanlong Tan
Journal:  Int Urol Nephrol       Date:  2016-02-09       Impact factor: 2.370

2.  Cytoreductive Surgery in the Management of Renal Tumours: Rationale, Current Evidence and Future Perspectives.

Authors:  Makarand V Khochikar
Journal:  Indian J Surg Oncol       Date:  2016-12-08

Review 3.  Surgery for metastatic renal cell cancer.

Authors:  Shomik Sengupta; Bradley C Leibovich; Michael L Blute; Horst Zincke
Journal:  World J Urol       Date:  2005-06-30       Impact factor: 4.226

4.  Inhibition of IL-17A suppresses enhanced-tumor growth in low dose pre-irradiated tumor beds.

Authors:  Eun-Jung Lee; Hyo Jin Park; Ik-Jae Lee; Won Woo Kim; Sang-Jun Ha; Yang-Gun Suh; Jinsil Seong
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

Review 5.  Renal cell carcinoma: An update for the practicing urologist.

Authors:  Sumanta K Pal; Paulo Bergerot; Robert A Figlin
Journal:  Asian J Urol       Date:  2015-04-16

6.  Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer.

Authors:  Elena Muraro; Carlo Furlan; Michele Avanzo; Debora Martorelli; Elisa Comaro; Aurora Rizzo; Damiana A Fae'; Massimiliano Berretta; Loredana Militello; Alessandro Del Conte; Simon Spazzapan; Riccardo Dolcetti; Marco Trovo'
Journal:  Front Immunol       Date:  2017-11-06       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.